FDA’s Decision Boosts Fulcrum Therapeutics; Macy’s Beats Q2 Estimates
- August 22nd, 2023
- 366 views
Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) surged over 30% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058, a potential treatment for sickle-cell disease (SCD).
$FULC was trading at $5.81 in pre-market, reflecting a gain of $1.89 (+48.21%).
Shifting focus, Macy’s, Inc. (NYSE: M) reported second quarter 2023 earnings at $0.26 per share, surpassing the consensus EPS estimate of $0.13. The company's quarterly sales amounted to $5.28 billion, slightly exceeding analysts' projected revenue of $5.09 billion.
In pre-market, $M was trading at $14.43, down $0.30 (-2.04%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login